Guided Therapeutics (GTHP) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to -$87000.0.
- Guided Therapeutics' Enterprise Value rose 5515.46% to -$87000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$87000.0, marking a year-over-year increase of 5515.46%. This contributed to the annual value of -$388000.0 for FY2024, which is 3434.86% up from last year.
- Latest data reveals that Guided Therapeutics reported Enterprise Value of -$87000.0 as of Q3 2025, which was up 5515.46% from -$185000.0 recorded in Q2 2025.
- Over the past 5 years, Guided Therapeutics' Enterprise Value peaked at -$87000.0 during Q3 2025, and registered a low of -$2.7 million during Q3 2022.
- For the 5-year period, Guided Therapeutics' Enterprise Value averaged around -$828421.1, with its median value being -$591000.0 (2023).
- In the last 5 years, Guided Therapeutics' Enterprise Value crashed by 583809.52% in 2021 and then surged by 7974.96% in 2024.
- Over the past 5 years, Guided Therapeutics' Enterprise Value (Quarter) stood at -$643000.0 in 2021, then crashed by 259.72% to -$2.3 million in 2022, then soared by 74.45% to -$591000.0 in 2023, then skyrocketed by 34.35% to -$388000.0 in 2024, then skyrocketed by 77.58% to -$87000.0 in 2025.
- Its last three reported values are -$87000.0 in Q3 2025, -$185000.0 for Q2 2025, and -$115000.0 during Q1 2025.